Volume 1 Issue 1

Case Report: Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumour in a Single Individual - the Choice of Therapy is a Shoo-In

Simon Kavanagh* and Jeffrey H. Lipton

Chronic myeloid leukaemia and gastrointestinal stromal tumours are rare diseases that, despite different genomic lesions, are sensitive to tyrosine kinase inhibition with imatinib. We report a case of a patient with both diagnoses and discuss the rationale for treatment.

Cite this Article: Kavanagh S, Lipton JH. Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumour in a Single Individual - the Choice of Therapy is a Shoo-In. Int J Blood Dis Dis. 2017; 1(1): 010-010.

Published: 11 October 2017

Editorial: Heparin induced Thrombocytopenia and its Tomorrow

Munawar Hussain*, Hans P Wendel and Frank K Gehring

Heparin Induced Thrombocytopenia (HIT) is an unwanted immunological reaction to the usage of heparin as an anticoagulant yielding thrombosis rather than the positive anticoagulant effects. The patients under heparin usage for several days are prone to HIT and HIT is connected to the risk of life threatening thrombosis by virtue of intravasal platelet aggregation. The destructive effects of HIT constitute thrombocytopenia and the thromboembolic complications risks in veins and arteries. Normally, HIT symptoms are observed within 4 to 15 days after initiation of heparin therapy and platelet count declines to less than half of the initial value [1].

Cite this Article: Hussain M, Wendel HP, Gehring FK. Heparin induced Thrombocytopenia and its Tomorrow. Int J Blood Dis Dis. 2017; 1(1): 007-009.

Published: 06 September 2017

Research Article: Platelet Proteomics in Chronic Myeloid Leukemia

Shilpita Karmakar, Debasis Banerjee and Abhijit Chakrabarti*

Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder resulting from the malignant transformation of a hematopoietic stem cell and is characterised by Philadelphia chromosome that generates a BCR-ABL protein with constitutive tyrosine kinase activity. Patients with CML have been reported with high platelet count, platelet dysfunction and thrombohaemorrhagic complications. The mechanism underlying such complications of platelets in CML is not well understood. In order to understand the factors responsible we have used 2DE coupled with MALDI TOF/TOF mass spectrometry based identification and characterization of altered proteins in CML platelet samples to investigate the factors responsible for thrombohemorrhagic complications and the results have been validated by immunoblotting experiments. Our study has revealed elevated levels of enzymes like GST, LDH, calcium binding protein, calreticulin, regulatory protein 14-3-3 ζ, INTEGRIN and HSP60 that points towards presence of activated platelets and increased metabolic activity of platelets in CML patients. The altered levels of chaperones, regulatory and enzyme proteins indicate towards regulation of INTEGRIN binding and platelet activation. This is the first comparative proteomics study of platelets in CML. The results could provide an insight into better understanding of the pathophysiology of the disease.

Cite this Article: Karmakar S, Banerjee D, Chakrabarti A. Platelet Proteomics in Chronic Myeloid Leukemia. Int J Blood Dis Dis. 2017; 1(1): 001-006.

Published: 14 June 2017

Submit ManuscriptSubmit Special Issue

Authors submit all Proposals and manuscripts via Electronic Form!

All Journals

Creative Commons License Open Access by SciRes Literature is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at www.scireslit.com.